Zhu Jiangang, Zhu Sheng, Yu Qiang, Wu Yong
Department of Hepato-Biliary-Pancreatic Surgery, Nanjing Medical University Affiliated Changzhou No. 2 People's Hospital, Changzhou 213000, China.
Transl Cancer Res. 2020 Mar;9(3):1806-1817. doi: 10.21037/tcr.2020.02.24.
Pancreatic cancer is an extensively concerned human malignancy around the globe, yet the potential therapeutic target remains to be further determined. MicroRNA and LncRNA have been reported to be involved in progression of pancreatic cancer, while the biological role of microRNA-574-3p (miR-574-3p) and FAM66C in pancreatic cancer development is poorly investigated.
Quantitative real-time PCR (qPCR) analysis was employed to detect the expression of miR-574-3p and FAM66C in pancreatic normal or cancerous tissues and cells. The proliferative and apoptosis signaling molecules were also examined via qPCR and western blot separately. Additionally, cell proliferation and apoptosis assay were performed via CCK8, colony formation and Annexin V-FITC apoptosis assay. Interaction between miR-574-3p and FAM66C was interrogated by luciferase reporter assay and RNA immunoprecipitation. Even more, a pancreatic cancer xenograft mice assay was implemented to illustrate the coordinating role of miR-574-3p and FAM66C in pancreatic cancer proliferation.
We found that levels of miR-574-3p were significantly higher in cancer tissues and cells compared to normal (P<0.05). Remarkably, the results indicated that depletion of miR-574-3p inhibited proliferation and promoted apoptosis of human pancreatic cancer cell lines. Additionally, FAM66C was demonstrated to interact with miR-574-3p and inhibit its expression. Significantly, FAM66C was proved to act as a tumor suppressor role via inhibiting cell proliferation and promoting cell apoptosis in pancreatic cancer. Moreover, FAM66C coordinated with miR-574-3p to regulate progression of xenograft tumor in the nude mice.
FAM66C-miR-574-3p axis mediates progression of pancreatic and might be the promising therapeutic target for pancreatic cancer patients.
胰腺癌是全球广泛关注的人类恶性肿瘤,但其潜在治疗靶点仍有待进一步确定。据报道,微小RNA(MicroRNA)和长链非编码RNA(LncRNA)参与胰腺癌的进展,而微小RNA-574-3p(miR-574-3p)和FAM66C在胰腺癌发生发展中的生物学作用研究较少。
采用定量实时PCR(qPCR)分析检测miR-574-3p和FAM66C在胰腺正常组织或癌组织及细胞中的表达。还分别通过qPCR和蛋白质印迹法检测增殖和凋亡信号分子。此外,通过CCK8、集落形成和膜联蛋白V-FITC凋亡检测进行细胞增殖和凋亡检测。通过荧光素酶报告基因检测和RNA免疫沉淀研究miR-574-3p与FAM66C之间的相互作用。甚至还进行了胰腺癌异种移植小鼠实验,以阐明miR-574-3p和FAM66C在胰腺癌增殖中的协同作用。
我们发现与正常组织相比,癌组织和癌细胞中miR-574-3p水平显著更高(P<0.05)。值得注意的是,结果表明miR-574-3p的缺失抑制了人胰腺癌细胞系的增殖并促进了其凋亡。此外,FAM66C被证明与miR-574-3p相互作用并抑制其表达。重要的是,FAM66C被证明在胰腺癌中通过抑制细胞增殖和促进细胞凋亡发挥肿瘤抑制作用。此外,FAM66C与miR-574-3p协同调节裸鼠体内异种移植肿瘤的进展。
FAM66C-miR-574-3p轴介导胰腺癌的进展,可能是胰腺癌患者有前景的治疗靶点。